SNX-111 neuron-specific calcium channel blocker: Phase II trial

Neurex Corp. (NXCO), Menlo Park,

Read the full 52 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE